New Drugs of 2011, Part 2

Michael A. Mancano, PharmD
Published Online: Wednesday, March 14, 2012
Follow Pharmacy_Times:

Pharmacy Times Office of Continuing Professional Education


New Drugs of 2011, Part 2

Michael A. Mancano, PharmD

Clinical Professor of Pharmacy Practice

Interim Chair, Department of Pharmacy Practice

Temple University School of Pharmacy; Philadelphia, PA

Clinical Consultant, Department of Pharmacy

Pennsylvania Hospital; Philadelphia, PA


Michael A. Mancano, PharmD, has no relevant affiliations or financial relationships to disclose.

Judy V. Lum, MPA; Ann C. Lichti, CCMEP; and Donna Fausak of the Pharmacy Times Office of Continuing Professional Education have no relevant affiliations or financial relationships to disclose related to this activity.


Educational Objectives

Upon completing the program, participants should be able to:

  1. Discuss the clinical indications of 8 new drugs approved by the FDA in 2011.
  2. Explain the mechanisms of action of the drugs discussed within this program.
  3. Recognize the clinically relevant drug interactions for the drugs reviewed in this program.
  4. Identify the most common adverse reactions for the discussed new drug approvals.
  5. Explain the approved dosing guidelines and recommended dosage adjustments for the drugs reviewed.

Target audience: Pharmacists

Type of activity: Knowledge

Release date: February 10, 2012

Expiration date: February 10, 2014

Estimated time to complete activity: 2.0 hours

Fee: There is no charge for taking this course online.

Click here to view this activity.



Related Articles
Getting involved in pharmacy organizations can promote leadership, teamwork, and time management skills. It’s important to find the right organization for you.
Live medication therapy management (MTM) reduces low-density-lipoprotein cholesterol significantly more than standard, chart-review MTM.
A combination of vemurafenib (Zelboraf) and experimental drug cobimetinib significantly reduces the development of secondary skin cancer.
ADHD medications are prone to the same abuse, misuse, and diversion as opioids.
Latest Issues
$auto_registration$